Scalper1 News
Valeant Pharmaceuticals (VRX) shares popped on upbeat guidance and as the addition of Actavis (ACT) to the Allergan-Valeant-Salix triangle lifted Valeant’s chances for an Allergan takeover. Valeant said it expects to beat third-quarter analyst views on revenue and its own cash EPS guidance when it reports on Oct. 20. It also sees same-store organic growth exceeding 15% in Q3, with its Bausch + Lomb segment delivering more than 10% organic growth. Scalper1 News
Scalper1 News